Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:QRVO 9 July 2025 - 26 January 2026

Qorvo stock drifts into earnings week: what to watch for QRVO before Tuesday’s report

Qorvo stock drifts into earnings week: what to watch for QRVO before Tuesday’s report

Qorvo shares fell 0.8% to $80.91 Friday ahead of its fiscal third-quarter earnings report, due after Tuesday’s close. Investors are watching for updates on handset demand, margins, and the pending Skyworks merger. About 1.5 million shares traded as the stock ranged from $80.12 to $82.10. Apple’s results Thursday could also influence sentiment on Qorvo and other suppliers.
26 January 2026
··
Skyworks Soars 18% on $22B Qorvo Merger – What’s Next for the Chipmaker?

Skyworks Soars 18% on $22B Qorvo Merger – What’s Next for the Chipmaker?

Skyworks shares jumped nearly 18% to around $89 on Oct. 28 after announcing a $22 billion cash-and-stock deal to acquire Qorvo. Qorvo holders will receive $32.50 and 0.96 Skyworks shares per Qorvo share. Skyworks recently reported Q3 revenue of $965 million and non-GAAP EPS of $1.33, both above forecasts. Wall Street remains cautious, with an average 12-month target of $70.90.
28 October 2025
···
Mixed-Signal and RF Components: June–July 2025 Industry Report

Mixed-Signal and RF Components: June–July 2025 Industry Report

Mixed-Signal Devices launched the MS4022 RF synthesizer on June 16, generating 675 MHz–22 GHz with 25 fs RMS phase jitter. Falcomm and GlobalFoundries reported 50% PAE in a 13 GHz CMOS power amp. 3GPP finalized Release 20 for early 6G research on June 18. The U.S. lifted EDA tool export restrictions for China on July 3, restoring access to Synopsys, Cadence, and Siemens.
9 July 2025
········

Stock Market Today

  • Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
    March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).
Go toTop